Loading...

UCSF Coronavirus Response: UCSF is partnering with public agencies to address the rapidly evolving outbreak and protect our communities. The UCSF COVID-19 Resources Website provides guidance and information for our patients, faculty, staff, trainees and learners.

Zoe Kopp, MD

Title(s)Resident Physician, Medicine
SchoolSchool of Medicine
Phone415-353-7900
ORCID ORCID Icon0000-0002-5058-4492 Additional info
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Rook JM, Winkelman TNA, Fox JA, Pierce JB, Oot AR, Blum JR, Feuerbach AM, Shahu A, Goldman ML, Kopp Z, Duffy E, Robledo-Gil T, Tran N, Davey CS, Henschen BL. Looking to the Future: Medical Students' Views on Health Care Reform and Professional Responsibility. Acad Med. 2019 09; 94(9):1361-1368. PMID: 31460934.
      View in: PubMed
    2. Kelleher C, Chapple C, Johnson N, Payne C, Homma Y, Hakimi Z, Siddiqui E, Evans C, Egan S, Kopp Z. Development of an overactive bladder assessment tool (BAT): A potential improvement to the standard bladder diary. Neurourol Urodyn. 2018 06; 37(5):1701-1710. PMID: 29360189.
      View in: PubMed
    3. Chapple CR, Kelleher CJ, Evans CJ, Kopp Z, Siddiqui E, Johnson N, Mako M. A Narrative Review of Patient-reported Outcomes in Overactive Bladder: What is the Way of the Future? Eur Urol. 2016 11; 70(5):799-805. PMID: 27160948.
      View in: PubMed
    4. Lenderking WR, Wyrwich KW, Stolar M, Howard KA, Leibman C, Buchanan J, Lacey L, Kopp Z, Stern Y. Reliability, validity, and interpretation of the dependence scale in mild to moderately severe Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2013 Dec; 28(8):738-49. PMID: 24363071.
      View in: PubMed
    5. Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology. 2012 Jul; 80(1):90-6. PMID: 22748867.
      View in: PubMed
    6. Brandt BA, Angün Ç, Coyne KS, Doshi S, Bavendam T, Kopp ZS. LUTS patient reported outcomes tool: linguistic validation in 10 European languages. Neurourol Urodyn. 2013 Jan; 32(1):75-81. PMID: 22674460.
      View in: PubMed
    7. Cotterill N, Goldman H, Kelleher C, Kopp Z, Tubaro A, Brubaker L. What are the best outcome measures when assessing treatments for LUTD?--achieving the most out of outcome evaluation: ICI-RS 2011. Neurourol Urodyn. 2012 Mar; 31(3):400-3. PMID: 22415657.
      View in: PubMed
    8. Coyne KS, Barsdorf AI, Thompson C, Ireland A, Milsom I, Chapple C, Kopp ZS, Bavendam T. Moving towards a comprehensive assessment of lower urinary tract symptoms (LUTS). Neurourol Urodyn. 2012 Apr; 31(4):448-54. PMID: 22396308.
      View in: PubMed
    9. Kelleher CJ, Dmochowski RR, Berriman S, Kopp ZS, Carlsson M. Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies. BJU Int. 2012 Aug; 110(3):392-400. PMID: 22129365.
      View in: PubMed
    10. Coyne KS, Margolis MK, Kopp ZS, Kaplan SA. Racial differences in the prevalence of overactive bladder in the United States from the epidemiology of LUTS (EpiLUTS) study. Urology. 2012 Jan; 79(1):95-101. PMID: 22055692.
      View in: PubMed
    11. Coyne KS, Kvasz M, Ireland AM, Milsom I, Kopp ZS, Chapple CR. Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States. Eur Urol. 2012 Jan; 61(1):88-95. PMID: 21831517.
      View in: PubMed
    12. Coyne KS, Gelhorn H, Thompson C, Kopp ZS, Guan Z. The psychometric validation of a 1-week recall period for the OAB-q. Int Urogynecol J. 2011 Dec; 22(12):1555-63. PMID: 21739328.
      View in: PubMed
    13. Mangera A, Chapple CR, Kopp ZS, Plested M. The placebo effect in overactive bladder syndrome. Nat Rev Urol. 2011 Jul 05; 8(9):495-503. PMID: 21727941.
      View in: PubMed
    14. Coyne KS, Sexton CC, Thompson C, Kopp ZS, Milsom I, Kaplan SA. The impact of OAB on sexual health in men and women: results from EpiLUTS. J Sex Med. 2011 Jun; 8(6):1603-15. PMID: 21492396.
      View in: PubMed
    15. Brubaker L, Khullar V, Piault E, Evans CJ, Bavendam T, Beach J, Yeh Y, Kopp ZS, Kelleher CJ, Trocio J. Goal attainment scaling in patients with lower urinary tract symptoms: development and pilot testing of the Self-Assessment Goal Achievement (SAGA) questionnaire. Int Urogynecol J. 2011 Aug; 22(8):937-46. PMID: 21373818.
      View in: PubMed
    16. Coyne KS, Sexton CC, Kopp ZS, Ebel-Bitoun C, Milsom I, Chapple C. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011 Nov; 108(9):1459-71. PMID: 21371240.
      View in: PubMed
    17. Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011 May; 77(5):1081-7. PMID: 21256571.
      View in: PubMed
    18. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011 Oct; 108(7):1132-8. PMID: 21231991.
      View in: PubMed
    19. Coyne KS, Cash B, Kopp Z, Gelhorn H, Milsom I, Berriman S, Vats V, Khullar V. The prevalence of chronic constipation and faecal incontinence among men and women with symptoms of overactive bladder. BJU Int. 2011 Jan; 107(2):254-61. PMID: 20590548.
      View in: PubMed
    20. Irwin DE, Milsom I, Chancellor MB, Kopp Z, Guan Z. Dynamic progression of overactive bladder and urinary incontinence symptoms: a systematic review. Eur Urol. 2010 Oct; 58(4):532-43. PMID: 20573443.
      View in: PubMed
    21. Nitti VW, Kopp Z, Lin AT, Moore KH, Oefelein M, Mills IW. Can we predict which patient will fail drug treatment for overactive bladder? A think tank discussion. Neurourol Urodyn. 2010 Apr; 29(4):652-7. PMID: 20432330.
      View in: PubMed
    22. Sexton CC, Coyne KS, Kopp ZS, Irwin DE, Milsom I, Aiyer LP, Tubaro A, Chapple CR, Wein AJ. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int. 2009 Apr; 103 Suppl 3:12-23. PMID: 19302498.
      View in: PubMed
    23. Coyne KS, Kaplan SA, Chapple CR, Sexton CC, Kopp ZS, Bush EN, Aiyer LP. Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS. BJU Int. 2009 Apr; 103 Suppl 3:24-32. PMID: 19302499.
      View in: PubMed
    24. Coyne KS, Wein AJ, Tubaro A, Sexton CC, Thompson CL, Kopp ZS, Aiyer LP. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int. 2009 Apr; 103 Suppl 3:4-11. PMID: 19302497.
      View in: PubMed
    25. Kaplan SA, Roehrborn CG, Chapple CR, Rosen RC, Irwin DE, Kopp Z, Aiyer LP, Mollon P. Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms. BJU Int. 2009 Apr; 103 Suppl 3:48-57. PMID: 19302502.
      View in: PubMed
    26. Wein AJ, Coyne KS, Tubaro A, Sexton CC, Kopp ZS, Aiyer LP. The impact of lower urinary tract symptoms on male sexual health: EpiLUTS. BJU Int. 2009 Apr; 103 Suppl 3:33-41. PMID: 19302500.
      View in: PubMed
    27. Coyne KS, Sexton CC, Kopp ZS, Luks S, Gross A, Irwin D, Milsom I. Rationale for the study methods and design of the epidemiology of lower urinary tract symptoms (EpiLUTS) study. BJU Int. 2009 Aug; 104(3):348-51. PMID: 19291251.
      View in: PubMed
    28. Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, Chapple CR, Kaplan S, Tubaro A, Aiyer LP, Wein AJ. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009 Aug; 104(3):352-60. PMID: 19281467.
      View in: PubMed
    29. Irwin DE, Milsom I, Kopp Z, Abrams P, Artibani W, Herschorn S. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol. 2009 Jul; 56(1):14-20. PMID: 19278775.
      View in: PubMed
    30. Sexton CC, Coyne KS, Vats V, Kopp ZS, Irwin DE, Wagner TH. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care. 2009 Mar; 15(4 Suppl):S98-S107. PMID: 19355804.
      View in: PubMed
    31. Van Kerrebroeck PE, Kelleher CJ, Coyne KS, Kopp Z, Brodsky M, Wang JT. Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health Qual Life Outcomes. 2009 Feb 18; 7:13. PMID: 19226471.
      View in: PubMed
    32. Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C. The economic impact of overactive bladder syndrome in six Western countries. BJU Int. 2009 Jan; 103(2):202-9. PMID: 19278532.
      View in: PubMed
    33. Irwin DE, Milsom I, Reilly K, Hunskaar S, Kopp Z, Herschorn S, Coyne KS, Kelleher CJ, Artibani W, Abrams P. Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. J Sex Med. 2008 Dec; 5(12):2904-10. PMID: 19090944.
      View in: PubMed
    34. Kelleher CJ, Tubaro A, Wang JT, Kopp Z. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int. 2008 Jul; 102(1):56-61. PMID: 18564231.
      View in: PubMed
    35. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008 Jun; 101(11):1388-95. PMID: 18454794.
      View in: PubMed
    36. Bradway C, Coyne KS, Irwin D, Kopp Z. Lower urinary tract symptoms in women-a common but neglected problem. J Am Acad Nurse Pract. 2008 Jun; 20(6):311-8. PMID: 18588658.
      View in: PubMed
    37. Coyne KS, Margolis MK, Thompson C, Kopp Z. Psychometric equivalence of the OAB-q in Danish, German, Polish, Swedish, and Turkish. Value Health. 2008 Dec; 11(7):1096-101. PMID: 18489500.
      View in: PubMed
    38. Cinar A, Hall SA, Link CL, Kaplan SA, Kopp ZS, Roehrborn CG, Rosen RC. Cluster analysis and lower urinary tract symptoms in men: findings from the Boston Area Community Health Survey. BJU Int. 2008 May; 101(10):1247-56. PMID: 18419698.
      View in: PubMed
    39. Hall SA, Cinar A, Link CL, Kopp ZS, Roehrborn CG, Kaplan SA, Rosen RC. Do urological symptoms cluster among women? Results from the Boston Area Community Health Survey. BJU Int. 2008 May; 101(10):1257-66. PMID: 18419699.
      View in: PubMed
    40. Coyne KS, Matza LS, Kopp ZS, Thompson C, Henry D, Irwin DE, Artibani W, Herschorn S, Milsom I. Examining lower urinary tract symptom constellations using cluster analysis. BJU Int. 2008 May; 101(10):1267-73. PMID: 18336611.
      View in: PubMed
    41. Irwin DE, Abrams P, Milsom I, Kopp Z, Reilly K. Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int. 2008 Jun; 101(11):1381-7. PMID: 18336602.
      View in: PubMed
    42. Irwin DE, Milsom I, Kopp Z, Abrams P. Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol. 2008 May; 53(5):1029-37. PMID: 18243515.
      View in: PubMed
    43. Piault E, Evans CJ, Espindle D, Kopp Z, Brubaker L, Abrams P. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire. Neurourol Urodyn. 2008; 27(3):179-90. PMID: 17565727.
      View in: PubMed
    44. Nicolson P, Kopp Z, Chapple CR, Kelleher C. It's just the worry about not being able to control it! A qualitative study of living with overactive bladder. Br J Health Psychol. 2008 May; 13(Pt 2):343-59. PMID: 17535499.
      View in: PubMed
    45. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006 Dec; 50(6):1306-14; discussion 1314-5. PMID: 17049716.
      View in: PubMed
    46. Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. Determining the importance of change in the overactive bladder questionnaire. J Urol. 2006 Aug; 176(2):627-32; discussion 632. PMID: 16813906.
      View in: PubMed
    47. Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology. 2006 Aug; 68(2 Suppl):3-8. PMID: 16908335.
      View in: PubMed
    48. Reeves P, Irwin D, Kelleher C, Milsom I, Kopp Z, Calvert N, Lloyd A. The current and future burden and cost of overactive bladder in five European countries. Eur Urol. 2006 Nov; 50(5):1050-7. PMID: 16753252.
      View in: PubMed
    49. Acquadro C, Kopp Z, Coyne KS, Corcos J, Tubaro A, Choo MS, Oh SJ. Translating overactive bladder questionnaires in 14 languages. Urology. 2006 Mar; 67(3):536-40. PMID: 16527574.
      View in: PubMed
    50. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol. 2006 Jun; 49(6):1079-86. PMID: 16460875.
      View in: PubMed
    51. Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006 Jan; 97(1):96-100. PMID: 16336336.
      View in: PubMed
    52. Wexler R, Bean C, Ito D, Kopp Z, LaCasse JA, Rea V. ME Cares: a statewide system engaging providers in disease management. Dis Manag. 2004; 7(2):136-52. PMID: 15228798.
      View in: PubMed
    53. Thaulow E, Jorgensen B, Doyle JJ, Casciano R, Casciano J, Kopp Z, Arikian S, Kim R. A pharmacoeconomic evaluation of results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES) in Norway and Canada. Int J Cardiol. 2002 Jul; 84(1):23-30; discussion 30-2. PMID: 12104059.
      View in: PubMed
    54. Riegel B, Carlson B, Kopp Z, LePetri B, Glaser D, Unger A. Effect of a standardized nurse case-management telephone intervention on resource use in patients with chronic heart failure. Arch Intern Med. 2002 Mar 25; 162(6):705-12. PMID: 11911726.
      View in: PubMed
    55. Hansson L, Lloyd A, Anderson P, Kopp Z. Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press. 2002; 11(1):35-45. PMID: 11926349.
      View in: PubMed
    Zoe's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (191) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (4) people
    _
    Similar People
    People who share similar concepts with this person.
    See all (60) people
    _
    Same Department
    Search Department
    ↑